## **BIOLIDICS LIMITED**

(Company Registration Number: 200913076M)

## NOTIFICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE INTENDED DISTRIBUTION OF BIOLIDICS' RAPID TEST KITS FOR NOVEL CORONAVIRUS 2019 – COMPLETION OF LISTING

The board of directors (the "Board") of Biolidics Limited (the "Company") refers to the announcement dated 13 April 2020 in relation to the above subject matter (the "Announcement"). Unless otherwise defined, capitalised terms used herein shall bear the same meanings ascribed to them in the Announcement.

Further to the Announcement, the Board is pleased to announce that the Company has completed the Listing of its COVID-19 Rapid Test Kits under Policy D on 17 April 2020 (Singapore time). With the completion of the Listing, the Company is now able to distribute, market and sell its COVID-19 Rapid Test Kits in the USA.

The Company wishes to highlight that its COVID-19 Test Kits are solely used for identifying antibodies to SARS-CoV-2 (the virus which causes the disease, the Novel Coronavirus 2019) and is limited to testing in laboratories or by healthcare workers at the point-of-care. Information along the lines of the following are also required to be provided in the test reports:

- The test has not been reviewed by the FDA;
- Negative results do not rule out SARS-CoV-2 infection particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals:
- Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status; and
- Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.

More details about Policy D can be found here: <a href="https://www.fda.gov/media/135659/download">https://www.fda.gov/media/135659/download</a>

## BY ORDER OF THE BOARD

Yee Pinh Jeremy Non-Executive Non-Independent Chairman 20 April 2020

This announcement has been prepared by Biolidics Limited (the "Company") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.